TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Improvement of amniotic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Improving the biophysical profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: frequency and duration of atrial fibrillation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective tumor response (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 68Ga-DOTATATE PET Positive Maximum Intensity Projection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain with QST
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain with VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline quality of life during breast cancer treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline psychological vulnerability during breast cancer treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevention of hypocalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Transcutaneous pCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Patient-reported hernia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: INR measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: first bowel sound in hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Muscle tone tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hoffman reflex (H-reflex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Survival of the patient
Endpoint domain: Mortality/survival
Primary endpoint: Frequencies of clinically significant lesions diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute radiation-induced toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Receipt of influenza vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Change in blood carbon dioxide level (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physician's Global Assessment (PGA) Ratings of Excellent or Cleared
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LiverMultiScan (LMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Activity Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Activity Scale for the Elderly (PASE)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: prognostic value of biomarkers in shortness of breath (SOB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cases for which vaccine is produced
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visceral Adipose Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Yale-Brown Obsessive Compulsive Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Re-hospitalization within 3 months of discharge
Endpoint domain: Mortality/survival
Primary endpoint: Deaths within 3 months of discharge
Endpoint domain: Mortality/survival
Primary endpoint: Comparison of bruit signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The concentration of carbon monoxide in exhaled air
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caecum Intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient comfort during colonoscopy - Visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of women who experience placenta accreta spectrum related massive blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of mothers admitted to intensive care unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days of maternal hospitalization after delivery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Treatment Success at day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Genetic variants detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response to biological treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative complications (Atelectasis, re-expansion failure, pneumonic infection)
Endpoint domain: Adverse events/effects
Primary endpoint: Numeric rating scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of significant pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Urinary Albumin-to-Creatinine Ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pain Intensity with Numeric Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain Intensity with Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Hospital Admission for Postoperative Pain Control
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Prevalence of NCRA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NCRA concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of correct answers by patient family
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Blood brain barrier permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of FGD-PET/CT to detect the primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic accuracy of FGD-PET/CT to detect lymph nodes metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic accuracy of FGD-PET/CT to detect distant lymph node metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Headache frequency and severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained viral response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Total Body Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Whole Body Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Body Weight From Baseline to Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial plasma carnosine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial plasma amino acid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial plasma lycopene concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Foot Strike Pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell-mediated immune responses (VZV specific T cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in serum prostate-specific antigen (PSA) by 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of unenhanced magnetic resonance imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in 24h urinary albumin excretion rate (UAER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in 24h urinary protein quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Duration of septic shock
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Complete Response (CR) and Very Good Partial Response (VGPR) at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocyte Lipid Accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Combined effect of Sofosbuvir and Daclatasvir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MMSS for Scar Halves Treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fidelity to the yoga interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance to the yoga interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients reacting to ED05
Endpoint domain: Adverse events/effects
Primary endpoint: Displacement Force Magnitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Displacement Force Vector
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in laboratory-induced falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Real life falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease activity prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year distant metastasis free survival
Endpoint domain: Mortality/survival
Primary endpoint: Facial expression recognition performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Emotional recall performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Autobiographical memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients With Remission, Low, Moderate or High Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Relative Change in Health Assessment Questionnaire - Disability Index Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Emicizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) of Emicizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Ratio of JNJ-56136379 Concentration and Total Radioactivity in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-last): Ratio of JNJ-56136379 Concentration and Total Radioactivity in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-infinity): Ratio of JNJ-56136379 Concentration and Total Radioactivity in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Panic Disorder Severity Scale - Self rated (PDSS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lumbar Pain Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical efficacy response (cure, failure, or indeterminate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of gastrointestinal disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cardiopulmonary efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Playground Hazards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in incidence of routine haematology and biochemistry abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AAA rupture
Endpoint domain: Mortality/survival
Primary endpoint: Disposable TIP duodenoscope performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time in tight glycemic control (70-180 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Accuracy of the Panic Screening Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for plasma rivaroxaban concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-tlast) for plasma rivaroxaban concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With One or More Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Days With Neither Daytime Nor Nighttime Heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to first smoke after abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in premenstrual complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-C measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal voluntary isometric strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: error rate at the hand laterality judgment task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermography of the hands after cooling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantified measures from FDG PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantified measures from DWI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantified measures from DCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality of dementia
Endpoint domain: Mortality/survival
Primary endpoint: Completing key steps toward receiving a kidney transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative usage of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum transferrin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of silicosis among study group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in CD4 T cell immune infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in CD8 T cell immune infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in apolipoprotein B (apoB) kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Gimatecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with therapeutic vancomycin serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of drug-related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of adverse events of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of Puncture Free Survival (PuFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypothermia upon discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 hour postprandial blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PFS for at Least 6 Months Without Non-protocol Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of patients achieving systolic blood pressure target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disabilities of the Arm, Shoulder and Hand Outcome Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Resolution of Post Operative Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with left ventricular hypertrophy or left ventricular dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Venous Thromboembolism (VTE) Related Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Rh alloimmunization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Echocardiographic assessment of LV function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Echocardiographic assessment of LV size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gesture frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stuttering frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective Intelligibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective Intelligibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response in POP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine environment in POP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Times Bronchoscope is Used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of PEU live stream
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Ability to Complete all 3 MCS Treatments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patient Reported Outcome Instrument: St. George's Respiratory Questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Crestal Soft Tissue Thickness (in mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Soft Tissue Thickness at 4mm Apical From Gingival Margin (in mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Palliative Response (Pain or Relief of Neurologic Symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assess the Acute and Late Toxicity of Spinal Radiosurgery
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Lack of Tumor Growth at Last Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Surface electromyographic activity of left biceps brachii muscle during isometric elbow flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Surface electromyographic activity of left triceps brachii muscle during isometric elbow flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Surface electromyographic activity of left biceps brachii muscle during concentric elbow flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Surface electromyographic activity of left triceps brachii muscle during concentric elbow flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Symptomatic relief of radiation-induced esophagitis grade ≥2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HCC occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Baseline aqueous humour cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glymphatic clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects With Pregnancy Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of patients who are pain free at 2 hours postdose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability as measured by subjective adverse experience reporting
Endpoint domain: Adverse events/effects